Cannabinoids and Their Actions: An Update

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2019 Apr 30

PMID 31032895

Citations 1

Authors

Stephen P H Alexander

Francisco Molina-Holgado

Affiliations

Soon will be listed here.

Abstract

This article is part of a themed section on 8 European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.

Citing Articles

Cannabinoids and their actions: An update.

Alexander S, Molina-Holgado F Br J Pharmacol. 2019; 176(10):1359-1360.

PMID: 31032895 PMC: 6487553. DOI: 10.1111/bph.14627.

References

Espejo-Porras F, Garcia-Toscano L, Rodriguez-Cueto C, Santos-Garcia I, de Lago E, Fernandez-Ruiz J . Targeting glial cannabinoid CB receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br J Pharmacol. 2018; 176(10):1585-1600. PMC: 6487601. DOI: 10.1111/bph.14216. View

Whalley B, Lin H, Bell L, Hill T, Patel A, Gray R . Species-specific susceptibility to cannabis-induced convulsions. Br J Pharmacol. 2018; 176(10):1506-1523. PMC: 6487554. DOI: 10.1111/bph.14165. View

Iannotti F, Pagano E, Moriello A, Alvino F, Sorrentino N, DOrsi L . Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol. 2018; 176(10):1568-1584. PMC: 6487563. DOI: 10.1111/bph.14460. View

Sticht M, Lau D, Keenan C, Cavin J, Morena M, Vemuri V . Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats. Br J Pharmacol. 2018; 176(10):1524-1540. PMC: 6487552. DOI: 10.1111/bph.14453. View

Malinowska B, Toczek M, Pedzinska-Betiuk A, Schlicker E . Cannabinoids in arterial, pulmonary and portal hypertension - mechanisms of action and potential therapeutic significance. Br J Pharmacol. 2018; 176(10):1395-1411. PMC: 6487561. DOI: 10.1111/bph.14168. View

Hinz B, Ramer R . Anti-tumour actions of cannabinoids. Br J Pharmacol. 2018; 176(10):1384-1394. PMC: 6487602. DOI: 10.1111/bph.14426. View

Alexander S, Molina-Holgado F . Cannabinoids and their actions: An update. Br J Pharmacol. 2019; 176(10):1359-1360. PMC: 6487553. DOI: 10.1111/bph.14627. View

Gobira P, Oliveira A, Gomes J, da Silveira V, Asth L, Bastos J . Opposing roles of CB and CB cannabinoid receptors in the stimulant and rewarding effects of cocaine. Br J Pharmacol. 2018; 176(10):1541-1551. PMC: 6487550. DOI: 10.1111/bph.14473. View

Garcia-Arencibia M, Molina-Holgado E, Molina-Holgado F . Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells. Br J Pharmacol. 2018; 176(10):1361-1369. PMC: 6487559. DOI: 10.1111/bph.14369. View

10.

Rea K, McGowan F, Corcoran L, Roche M, Finn D . The prefrontal cortical endocannabinoid system modulates fear-pain interactions in a subregion-specific manner. Br J Pharmacol. 2018; 176(10):1492-1505. PMC: 6487600. DOI: 10.1111/bph.14376. View

11.

Malek N, Starowicz K . Joint problems arising from lack of repair mechanisms: can cannabinoids help?. Br J Pharmacol. 2018; 176(10):1412-1420. PMC: 6487548. DOI: 10.1111/bph.14204. View

12.

Fernandez-Ruiz J . The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. Br J Pharmacol. 2018; 176(10):1370-1383. PMC: 6487558. DOI: 10.1111/bph.14382. View

13.

Alhouayek M, Rankin L, Gouveia-Figueira S, Fowler C . Interferon γ treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells. Br J Pharmacol. 2018; 176(10):1470-1480. PMC: 6487551. DOI: 10.1111/bph.14135. View

14.

Myers A, Siegele P, Foss J, Tuma R, Ward S . Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Br J Pharmacol. 2018; 176(10):1552-1567. PMC: 6487562. DOI: 10.1111/bph.14147. View

15.

Alexander S, Randall M . Cannabinoids and their actions. Br J Pharmacol. 2007; 152(5):557-8. PMC: 3230045. DOI: 10.1038/sj.bjp.0707483. View

16.

Tham M, Yilmaz O, Alaverdashvili M, Kelly M, Denovan-Wright E, Laprairie R . Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol. 2018; 176(10):1455-1469. PMC: 6487556. DOI: 10.1111/bph.14440. View

17.

Attili B, Celen S, Ahamed M, Koole M, Van den Haute C, Vanduffel W . Preclinical evaluation of [ F]MA3: a CB receptor agonist radiotracer for PET. Br J Pharmacol. 2018; 176(10):1481-1491. PMC: 6487560. DOI: 10.1111/bph.14564. View

18.

Okine B, Gaspar J, Finn D . PPARs and pain. Br J Pharmacol. 2018; 176(10):1421-1442. PMC: 6487555. DOI: 10.1111/bph.14339. View

19.

Hansen H, Vana V . Non-endocannabinoid N-acylethanolamines and 2-monoacylglycerols in the intestine. Br J Pharmacol. 2018; 176(10):1443-1454. PMC: 6487557. DOI: 10.1111/bph.14175. View